{"protocolSection":{"identificationModule":{"nctId":"NCT00847704","nctIdAliases":["NCT00600184"],"orgStudyIdInfo":{"id":"IRB 4005"},"organization":{"fullName":"Oregon Health and Science University","class":"OTHER"},"briefTitle":"Clinic-Based AMES Treatment of Stroke","officialTitle":"Clinic-Based Ames Treatment of the Lower Extremity in Chronic Stroke Subjects"},"statusModule":{"statusVerifiedDate":"2016-11","overallStatus":"TERMINATED","whyStopped":"Funding not available.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-04"},"primaryCompletionDateStruct":{"date":"2009-11","type":"ACTUAL"},"completionDateStruct":{"date":"2009-11","type":"ACTUAL"},"studyFirstSubmitDate":"2009-02-18","studyFirstSubmitQcDate":"2009-02-18","studyFirstPostDateStruct":{"date":"2009-02-19","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-12-17","resultsFirstSubmitQcDate":"2016-11-23","resultsFirstPostDateStruct":{"date":"2017-01-23","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-11-23","lastUpdatePostDateStruct":{"date":"2017-01-23","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Paul J. Cordo","investigatorTitle":"Principal Investigator","investigatorAffiliation":"Oregon Health and Science University"},"leadSponsor":{"name":"Oregon Health and Science University","class":"OTHER"},"collaborators":[{"name":"AMES Technology","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This study investigates whether assisted movement with biofeedback and muscle vibration applied to the lower limb reduces impairment and improves gait.","detailedDescription":"The hypothesis of this study is that chronic stroke survivors, more than one year post-stroke, with a motor problems in the lower extremity will be able to walk and move the affected leg better after 30 treatments with a new robotic therapy device, the AMES device. The device rotates the ankle while vibrators stimulate the tendons attached to muscles that move the ankle. Testing will be done before, during and after the treatments to determine response to the therapy."},"conditionsModule":{"conditions":["Stroke","Cerebrovascular Accident"],"keywords":["Stroke","Rehabilitation","Robotics"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":3,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Test treatment group","type":"EXPERIMENTAL","description":"Device: Assisted movement and enhanced sensation","interventionNames":["Device: Assisted movement and enhanced sensation"]}],"interventions":[{"type":"DEVICE","name":"Assisted movement and enhanced sensation","description":"Each subject will be tested before, after the 10 week treatment period and then 3 months later. Treatment sessions will occur 3 times per week and last approximately 30 minutes per treatment. The device will measure 3 of the functional tests prior to each treatment session.","armGroupLabels":["Test treatment group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Fugl-Meyer Assessment of the Lower Extremity","description":"Gold standard for motor impairment in individuals with stroke. A scale measuring tone, range-of-motion and synergies of the lower limb with a range of 0-34, higher scores referring to improved motor ability. The assessment includes 7 subscales, the scores of which are summed to arrive at a total score.","timeFrame":"Pre-training, After 30 training sessions (8-10 weeks), 3-Month Follow-up"}],"secondaryOutcomes":[{"measure":"Timed 10-Meter Walk","description":"Gait Assessment - Time","timeFrame":"Pre-training, After 30 training sessions (8-10 weeks), 3-Month Follow-up"},{"measure":"Stroke Impact Scale","description":"The Stroke Impact Scale is a self-assessment questionnaire concerning activities of daily living. There are 8 sub-scales, each of which is summed as a raw score (range of 0-100) and then transformed as follows:\n\nTransformed Scale=\\[(Actual raw score-lowest possible raw score)/Possible raw score range\\]x100.\n\nThus, the maximum possible score for the entire measure is 800. A higher score indicates a higher level of functioning.","timeFrame":"Pre-training, After 30 training sessions (8-10 weeks), 3-Month Follow-up"},{"measure":"Spasticity (Modified Ashworth) Scale","description":"Measure of the total Ashworth scoring for increased muscle tone in the ankle flexors, ankle extensors, knee flexors, and knee extensors in the affected leg of stroke subjects. The scale range is from 0-5, with higher levels representing more exaggerated tone.","timeFrame":"Pre-training, After 30 training sessions (8-10 weeks), 3-Month Follow-up"},{"measure":"Strength Test","description":"Measurement of ankle dorsiflexion/plantarflexion isometric strength (change-score from average of first 3 training sessions and last 3 training sessions).","timeFrame":"First 3 training sessions (week 1-2); Last 3 training sessions (week 9-10)"},{"measure":"Active Motion Test","description":"Tracking task. Active joint position control between dorsiflexion/plantarflexion (change-score from average of first 3 training sessions and last 3 training sessions). The score is based on the amount of time that the participant is able to position the joint in a 3 deg-wide target zone presented on a video screen.","timeFrame":"First 3 training sessions (week 1-2); Last 3 training sessions (week 9-10)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 12 months post-stroke\n* Cognitively and behaviorally capable of complying with the regimen\n* Functioning proprioception\n* Less than 50% of normal strength in the affected ankle, but able to stand with or without assistive devices\n\nExclusion Criteria:\n\n* Fractures of treated limb resulting in loss of range of motion\n* Spinal cord injury\n* Deep vein thrombosis\n* Peripheral nerve injury or neuropathy in the limb affected with motor disability\n* Osteoarthritis limiting range of motion\n* Skin condition not tolerant of device\n* Progressive neurodegenerative disorder\n* Uncontrolled seizure disorder\n* Botox treatment within the last 5 months\n* Baclofen pump","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Paul J. Cordo, PhD","affiliation":"AMES Technology Inc./Oregon Health and Science University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Oregon Health and Science University","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}}]},"referencesModule":{"references":[{"pmid":"18645190","type":"BACKGROUND","citation":"Cordo P, Lutsep H, Cordo L, Wright WG, Cacciatore T, Skoss R. Assisted movement with enhanced sensation (AMES): coupling motor and sensory to remediate motor deficits in chronic stroke patients. Neurorehabil Neural Repair. 2009 Jan;23(1):67-77. doi: 10.1177/1545968308317437. Epub 2008 Jul 21."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Test Group","description":"Device: Assisted movement and enhanced sensation"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"3"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Stroke \\>1 yr prior to enrollment Able to stand independently \\<50% normal strength in affected leg Functioning proprioception in affected leg","groups":[{"id":"BG000","title":"Test Group","description":"Device: Assisted movement and enhanced sensation\n\nAssisted movement and enhanced sensation: Each subject will be tested before, after the 10 week treatment period and then 3 months later. Treatment sessions will occur 3 times per week and last approximately 30 minutes per treatment. The device will measure 3 of the functional tests prior to each treatment session.\n\nAssisted movement and enhanced sensation: Thirty treatment sessions on the AMES device, each session 30 minutes of cyclic rotation of the ankle with tendon vibration. Testing before, during, and after treatments to evaluate response to treatments."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"2"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"67","spread":"2.0"}]}]}]},{"title":"Gender","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"1"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}]}]},{"title":"Time since stroke","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Months","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"113.5","spread":"85.5"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Fugl-Meyer Assessment of the Lower Extremity","description":"Gold standard for motor impairment in individuals with stroke. A scale measuring tone, range-of-motion and synergies of the lower limb with a range of 0-34, higher scores referring to improved motor ability. The assessment includes 7 subscales, the scores of which are summed to arrive at a total score.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Pre-training, After 30 training sessions (8-10 weeks), 3-Month Follow-up","groups":[{"id":"OG000","title":"Test Group","description":"Group receiving AMES therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"21.0","spread":"1.0"}]}]},{"title":"Post-treatment","categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":"0.5"}]}]},{"title":"3 Month Follow-up","categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Timed 10-Meter Walk","description":"Gait Assessment - Time","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"seconds","timeFrame":"Pre-training, After 30 training sessions (8-10 weeks), 3-Month Follow-up","groups":[{"id":"OG000","title":"Test Group","description":"Group receiving AMES therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"12.465","spread":"0.055"}]}]},{"title":"Post-treatment","categories":[{"measurements":[{"groupId":"OG000","value":"13.66","spread":"0.34"}]}]},{"title":"3 Month Follow-up","categories":[{"measurements":[{"groupId":"OG000","value":"13.27","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Stroke Impact Scale","description":"The Stroke Impact Scale is a self-assessment questionnaire concerning activities of daily living. There are 8 sub-scales, each of which is summed as a raw score (range of 0-100) and then transformed as follows:\n\nTransformed Scale=\\[(Actual raw score-lowest possible raw score)/Possible raw score range\\]x100.\n\nThus, the maximum possible score for the entire measure is 800. A higher score indicates a higher level of functioning.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Pre-training, After 30 training sessions (8-10 weeks), 3-Month Follow-up","groups":[{"id":"OG000","title":"Test Group","description":"Group receiving AMES therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"234.5","spread":"9.5"}]}]},{"title":"Post-treatment","categories":[{"measurements":[{"groupId":"OG000","value":"258","spread":"4.0"}]}]},{"title":"3 Month Follow-up","categories":[{"measurements":[{"groupId":"OG000","value":"251.5","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Spasticity (Modified Ashworth) Scale","description":"Measure of the total Ashworth scoring for increased muscle tone in the ankle flexors, ankle extensors, knee flexors, and knee extensors in the affected leg of stroke subjects. The scale range is from 0-5, with higher levels representing more exaggerated tone.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Pre-training, After 30 training sessions (8-10 weeks), 3-Month Follow-up","groups":[{"id":"OG000","title":"Test Group","description":"Group receiving AMES therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"2.0"}]}]},{"title":"Post-treatment","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.5"}]}]},{"title":"3 Month Follow-up","categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Strength Test","description":"Measurement of ankle dorsiflexion/plantarflexion isometric strength (change-score from average of first 3 training sessions and last 3 training sessions).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Newton meters","timeFrame":"First 3 training sessions (week 1-2); Last 3 training sessions (week 9-10)","groups":[{"id":"OG000","title":"Test Group","description":"Group receiving AMES therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"classes":[{"title":"Dorsiflexion","categories":[{"measurements":[{"groupId":"OG000","value":"33.7","spread":"41.4"}]}]},{"title":"Plantarflexion","categories":[{"measurements":[{"groupId":"OG000","value":"31.5","spread":"8.8"}]}]}]},{"type":"SECONDARY","title":"Active Motion Test","description":"Tracking task. Active joint position control between dorsiflexion/plantarflexion (change-score from average of first 3 training sessions and last 3 training sessions). The score is based on the amount of time that the participant is able to position the joint in a 3 deg-wide target zone presented on a video screen.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Seconds","timeFrame":"First 3 training sessions (week 1-2); Last 3 training sessions (week 9-10)","groups":[{"id":"OG000","title":"Test Group","description":"Group receiving AMES therapy"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"0.2"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"1 year, 1 month","description":"Verbal inquiry at the beginning of each training session.","eventGroups":[{"id":"EG000","title":"Test Treatment Group","description":"Device: Subjects receiving AMES treatments.","seriousNumAffected":0,"seriousNumAtRisk":3,"otherNumAffected":1,"otherNumAtRisk":3}],"otherEvents":[{"term":"Fall","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Loss of balance during moving","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Early termination due to lack of funding lead to only 2 subjects treated and analyzed."},"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Paul J. Cordo","organization":"Oregon Health & Science University","email":"cordop@ohsu.edu","phone":"503-418-2520"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T1303","name":"Chronic Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":true}